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Abstract 
Background: There is need to assess the developmental neurotoxicity of fluoride. Our 
knowledge of prenatal fluoride exposure is challenged as few population-based studies 
have been conducted and these generally date back several decades, provide incomplete 
data on sociodemographic variables, and have methodological limitations.  
Objective: To measure urinary and plasma fluoride levels across three time points in 
pregnant mothers who were enrolled in the Early Life Exposures in Mexico to 
Environmental Toxicants (ELEMENT) birth cohort study. 
Methods: Fluoride levels were characterized in archived urine and plasma from 872 
pregnant mothers sampled from the ELEMENT cohort. Various statistical methods were 
used to analyze the fluoride data with particular consideration for changes across three 
stages of pregnancy and against sociodemographic variables.  
Results: All samples had detectable levels of fluoride. The mean urinary and plasma 
fluoride levels were 0.91 and 0.0221 mg/L respectively, and these were not statistically 
different across three stages of pregnancy.  Fluoride levels correlated across the stages of 
pregnancy studied, with stronger correlations between neighboring stages.  Urinary 
fluoride changed as pregnancy progressed with levels increasing until ~23 weeks and 
then decreasing until the end of pregnancy.   For plasma fluoride, there was a decreasing 
trend but this was not of statistical significance.  Creatinine-adjusted urinary fluoride 
levels did not associate consistently with any of the sociodemographic variables studied.   
Conclusions: This study provides the most extensive characterization to date of fluoride 
exposure throughout pregnancy. These results provide the foundation to explore 
exposure-related health outcomes in the ELEMENT cohort and other studies.  
Introduction  
 
Community water fluoridation has been used for nearly 60 years to reduce the 
prevalence of dental caries. An estimated 210 million people in the United States (CDC, 
2013) and millions more across 30+ countries drink water with fluoride levels currently 
considered optimal for caries prevention (Fawell et al., 2006).  In addition to water, 
population-level exposures in some areas are achieved via the fluoridation of salt (e.g., 
certain regions of Mexico; Martinez-Mier et al. 2009; Jimenez-Farfan et al. 2011) or milk 
(Peterson et al., 2015; Weitz et al., 2015). Despite clear benefits in relation to dental 
caries, there remains an intense debate over the safety of fluoridation because of evidence 
demonstrating that excessive fluoride intake is associated with adverse effects on teeth 
(DenBesten and Li, 2011), bones (Chachra et al. 2008), and childhood cognition (Tang et 
al., 2008). This controversy, in part, spurred a review of the health literature by the U.S. 
National Research Council (NRC, 2006). The resulting NRC report called for more 
research to address the potential impacts of population level fluoride exposure, 
particularly among vulnerable populations including pregnant women and children.  
 
Based on epidemiological and animal evidence, there is growing concern that 
fluoride is a developmental neurotoxicant. For example, a systematic review by Choi et 
al. (2012) that included 27 epidemiological studies found reduced children’s intelligence 
associated with high fluoride exposures.  Reports of developmental impacts are plausible 
given that maternally ingested fluoride has been shown to reach the fetus through the 
umbilical cord or placenta. Maternal blood fluoride, for example, is moderately correlated 
with cord blood, indicating that at least some fluoride moves from the maternal 
compartment to the fetus (Gedalia et al., 1961; Shimonovitz et al., 1995). Fluoride levels 
in the fetal brain (Du et al., 2008; Narayanaswamy and Piler, 2009) and teeth (Parker and 
Bawden, 1986) have been shown to increase in parallel with maternal exposures. Taken 
together, these findings suggest that the fetus is exposed to fluoride, and that maternal 
fluoride levels can be used as a proxy for fetal exposure. However, very few studies have 
characterized prenatal exposures to fluoride. 
 
Fluoride exposure in pregnant women, to our knowledge, has been reported in 
very few population-based studies (Caldera et al., 1988; Gardner et al., 1952; Gedalia et 
al., 1959; Malhotra et al., 1993).  These studies are limited in that, for example, they 
generally date back several decades, provide incomplete data on socioeconomic or 
demographic variables that could help interpret exposures, and have methodological 
limitations (e.g., they lack robust sample sizes, multiple biomarkers, and repeated 
measures). Given the limitations of the aforementioned studies and a need to better 
resolve prenatal exposures, the current study aimed to increase our understanding of 
developmental fluoride exposures by measuring maternal levels of fluoride over the 
course of pregnancy. To achieve this, we measured urinary and plasma fluoride levels 
across three time points in pregnant mothers who were enrolled in the Early Life 
Exposures in Mexico to Environmental Toxicants (ELEMENT) birth cohort study.  
 
  
Methods 
 
Study Population 
The institutional review boards of the National Institute of Public Health of 
Mexico, University of Michigan, Indiana University, the University of Toronto, and 
participating clinics approved the study procedures. Study participants were recruited 
between 1997 and 2006 from three clinics of the Mexican Institute of Social Security in 
Mexico City (Mexico) as part of the ELEMENT study. Pertinent details of the three 
cohorts that make up the ELEMENT study, including for example recruitment, collection 
of demographic information such as maternal age, education, marital status and smoking 
status during pregnancy, and collection and archival of pregnancy urine and plasma can 
be found elsewhere (Hu et al., 2006; Afeiche et al., 2011).  Of particular note is that all 
urine samples consisted of early morning 2nd voided specimens collected at our study 
clinic; and all plasma samples were collected using special methods to prevent 
contamination and hemolysis (Smith et al., 2002)  
 
The ELEMENT population consists of 2,161 mothers (Figure 1).  Here, the study 
population was drawn from women who had prenatal visits associated with archived 
prenatal urine or plasma sample with adequate volume for additional analyses (i.e., they 
were drawn from two of the three ELEMENT cohorts).   Of the 997 women in the source 
population, 872 contributed at least one urine or plasma sample during the early, mid, and 
late stages of pregnancy; 825 women contributed a total of 1,520 urine samples, and 330 
women contributed a total of 627 plasma fluoride samples. The gestational week (i.e., 
self-reported date of last menstrual period) the samples were donated and the child’s sex 
were recorded.  
 
Fluoride in Urine Samples 
The free ionic form of fluoride was measured using a micro diffusion method 
(Martinez-Mier et al., 2011) at the University of Michigan School of Public Health 
(UMSPH). Briefly, urine was diluted with equal parts Milli-Q water in a petri dish, and 
allowed to react for 20-24 hours with 3 M sulfuric acid saturated with 
hexamethyldisiloxane (HMDS). The diffused fluoride was collected in 0.05 M of sodium 
hydroxide that was spotted on the interior of the petri dish cover. Following 
neutralization with 0.25 M of acetic acid, the concentration of fluoride in this solution 
was determined using an ion-selective electrode (Orion Fluoride Combination Electrode).  
 
Urinary reference materials obtained from the Institut National de Santé Publique du 
Québec (INSPQ) were used to gauge analytical accuracy and precision. In addition, each 
batch run contained procedural blanks and replicate runs. The average recovery rate 
(analytical accuracy) for the reference materials was 100%. The mean relative standard 
deviation (analytical precision) for all samples was below 20% for samples containing 
less than or equal to 0.2 mg/L of fluoride and below 10% for samples with a fluoride 
concentration above 0.2 mg/L. Note, samples that had a coefficient of variation >20% 
were re-analyzed if there was urine remaining.		The analytical detection limit (mean: 
0.00656mg/L) was calculated as the mean blank value plus two times the standard 
deviation. 	
 
 
An additional 390 urine samples were measured for fluoride content at the Indiana 
University Oral Health Research Institute (OHRI) using a similar procedure detailed in 
Martinez-Mier et al. (2011) with similar outcomes. Further, a validation study was 
conducted to determine the degree of similarity between samples measured at UMSPH 
versus at OHRI. Forty-eight samples were measured in both labs.  A careful statistical 
assessment of the resulting urinary fluoride levels revealed a correlation coefficient of 
0.92 between measures taken by both labs.  
 
Creatinine in Urine Samples  
Urinary creatinine was measured using a MicroLab AT Plus (Hamilton Co., Reno, 
NV, USA) and Microplate Spectrophotometer (SpectraMax 340, Molecular Devices, 
Sunnyvale, CA, USA) at the University of Michigan. To account for variations in urine 
dilution at the time of measurement, urinary fluoride concentrations were adjusted for 
creatinine (Petersen et al. 2014).  This was done by dividing the concentration of fluoride 
in the maternally-derived sample (MUF) by the sample’s creatinine concentration 
(MUC), and multiplying by the average creatinine concentration of samples available at 
each trimester (MUCaverage) using the formula: (MUF /MUC) x MUCaverage. The values 
(mg/L) for MUCaverage at each trimester were 100.8, 81.6, and 72.4. 
 
Fluoride in Plasma Samples 
Plasma samples were measured for fluoride at the Indiana University Oral Health 
Research Institute (OHRI) using the hexamethyldisiloxane (HMDS) microdiffusion 
method of Taves (1968) as modified by Martinez-Mier et al. (2011). Briefly, plasma 
sample diluted 2:1 with diH2O was pipetted into a plastic Petri dish, with a trap solution 
of 0.075 N sodium hydroxide (NaOH) placed on each dish lid.  Each dish was 
immediately sealed.  Next, HMDS-saturated 3 N SO4 was introduced into each sample 
via a small hole burned into each lid.  The hole was sealed immediately with petroleum 
jelly. During overnight diffusion, fluoride was released and trapped in the NaOH. The 
trap was recovered and buffered to pH 5.2 with acetic acid (CH3COOH). The recovered 
solution was adjusted to a final volume of 20 ml with diH2O. A standard fluoride curve 
was prepared from similarly diffused fluoride standard solutions and used to determine 
fluoride content of each plasma sample.  Millivolt readings were measured using a 
fluoride micro-electrode (Microelectrodes, Inc MI-SO) and pH/ISE meter (Orion Dual 
Star or equivalent). Duplicate analyses were done in sets of approximately 30-40 
samples, and analytical precision of these measurements was less than 10%.   
 
Data Analysis 
 Summary measures (e.g., mean, median, standard deviation, minimum, 
maximum, and 10th, 25th, 75th and 90th percentiles) were calculated for urinary fluoride 
and plasma fluoride samples. Spearman correlation coefficients were generated to show 
the relationship between the biomarkers of exposure and other demographic variables.  
To assess the stability of the two biomarkers throughout pregnancy, intra-class 
correlation coefficients (ICC) were calculated. The ICC calculations excluded the top and 
bottom 1% of the observations and were calculated using log-transformed concentrations 
to stabilize the variance components. Bivariate analyses examining the crude associations 
between fluoride measures at each trimester and covariates were conducted using simple 
linear regression. Generalized additive mixed models, adjusted for maternal education, 
age, marital status, smoking status (never smokers, history of smoking but not smoking 
during pregnancy, or smoking during pregnancy), and child’s sex were run to assess their 
effect on maternal urine and plasma levels during pregnancy, as well as to examine the 
time trend of the fluoride concentrations during gestation. The selection of model 
variables was guided through a combination of our review of the literature, an 
understanding of fluoride’s toxicokinetics, and exploration of variables through 
correlative analyses.  Data were analyzed using R 3.0.0 (RStudio, Inc.) and SAS 9.3 
(SAS Institute Inc. Cary, NC). Results are shown as means ± standard deviation unless 
otherwise indicated. 
  
Results 
 
Fluoride measurements were made in urine and/or plasma from ELEMENT 
mothers (N=872) for whom we had at least one prenatal biomarker (Figure 1).  
Characteristics of these mothers (age: 26.6 ± 5.4 years; maternal education: 10.7 ± 3 
years; 89.4% married or cohabitating) were not statistically different from mothers (N= 
125) excluded due to not having any prenatal biomarkers measured.  Pregnant mothers 
were sampled at 13.5 (± 2.3; range 0-26), 25.3 (± 2.4; range 15-37), and 34.5 (± 2.1; 
range 22-43) weeks of pregnancy.  We acknowledge that some women were sampled at 
zero weeks of pregnancy as certain women who wanted to get pregnant were enrolled 
into ELEMENT Cohort 2. 
 
The number of mothers for whom we have prenatal fluoride biomarker 
measurements from early, mid and late pregnancy (Nurine=505, 454, 335; Nurine creatinine-
adjusted=414, 186, 231; Nplasma=220, 255, 152, respectively), and those for whom we have 
one, two, or all three of the measurements (Nurine=314, 327, 184; Nurine creatinine-adjusted=220, 
224, 71; Nplasma =113, 137, 80 respectively) varied.  
 
Every urine and plasma sample investigated had detectable levels of fluoride 
(Table 1). The overall mean urinary fluoride level was 0.91 mg/L, and the mean values 
across the three stages of pregnancy that were studied here did not differ (Figure 2a).  The 
creatinine adjusted urinary fluoride results are not different from the unadjusted values 
(matched results are summarized in Supplemental Table 1).  Plasma fluoride levels were 
~40-times lower than urinary fluoride levels.  The overall mean plasma fluoride value 
was 0.0221 mg/L.  Like in the urine, the mean plasma fluoride level did not differ across 
the three stages of pregnancy that were studied here (Figure 2b).  
 
The consistency of urinary and plasma fluoride concentrations across the three 
stages of pregnancy was studied (Table 2).  In urine, fluoride levels were correlated 
across the three stages of pregnancy with Spearman coefficients ranging from 0.21 to 
0.39.  For plasma, fluoride levels correlated between neighboring time periods (i.e., 
between early and mid stages, and mid and late stages) but were not correlated between 
early and late stages of pregnancy.   Analyses of the correlation between urinary and 
plasma fluoride levels was explored but were limited during certain stages of pregnancy 
owing to low sample sizes.  In general there was a lack of correlation between these two 
biomarkers, though a significant correlation was found in fluoride levels between urine 
and plasma of mothers sampled during early stages of pregnancy. Across the three stages 
of pregnancy, maternal urinary fluoride and plasma values (Figure 2) were not different 
and remained fairly stable as pregnancy progressed. As a summary measure of 
consistency in fluoride concentrations across the three stages of pregnancy from which 
we sampled biomarkers, the ICC for urine was 0.25 and for plasma was 0.39.  
 
 To increase understanding of the fluoride biomarkers, biomarker values were 
stratified according to key sociodemographic variables (Table 3).  For simplicity here we 
present fluoride biomarker values that have been averaged across the three sampling 
periods.  The analyses shows that urinary fluoride was associated with the cohort from 
which the mothers were drawn and their level of education, but these differences did not 
remain once the urinary fluoride was adjusted for creatinine. 
 
Two linear mixed effects models, with repeated measures of either creatinine-adjusted 
urine fluoride or plasma fluoride as the outcome, were run after adjusting for maternal 
education, age, marital status, smoking status (never, during pregnancy or smoking 
history but no during pregnancy), and child’s sex. Urinary fluoride changed as pregnancy 
progressed with levels increasing until 22 to 23 weeks and then decreasing until the end 
of pregnancy (Figures 3a and 3b).   For plasma fluoride (Figures 3c and 3d), there was a 
decreasing trend but this was not of statistical significance.   In another analysis, plasma 
fluoride was included as a dependent variable in the urinary fluoride model, and urinary 
fluoride as a dependent variable in the plasma model, but no significant associations were 
detected between the two biomarkers.  
 
 
  
Discussion 
 
To our understanding, this is the first large exposure assessment of fluoride during 
multiple time points of pregnancy using two different biomarkers (urine, plasma). Where 
other studies have provided exposure data for the last trimester and delivery, our work 
examined exposure trends from the first month of pregnancy through delivery and found 
that levels in urine and plasma are relatively stable. Specifically, the population-average 
pattern of fluoride levels over time were fairly stable (see Figure 3) though within women 
there was less consistency of the measurements throughout pregnancy (e.g., ICC of 0.25 
for urine).   The work also shows that key sociodemographic variables are not associated 
with fluoride biomarkers in this population.  In addition, our study extends upon previous 
fluoride biomarker ones in that we extensively document analytical quality control 
parameters (e.g., accuracy and precision), have measures of both plasma and urine, 
provide relatively larger sample sizes that are drawn from across multiple time points of 
pregnancy.   
   
In the current study, maternal urinary fluoride levels in spot urine ranged upwards 
of ~3 mg/L with an overall mean value of 0.8 mg/L, and plasma fluoride ranged upwards 
of ~0.1 mg/L with an overall mean value of 0.02 mg/L.  In general, these values were not 
associated with any of the sociodemographic variables that we investigated. Here we 
compare these fluoride levels to values reported elsewhere, albeit the number of studies 
from which we could draw comparisons was quite limited. In a study of 117 healthy 
pregnant women living in Jerusalem, fluoride levels in spot urine samples from ranged 
from detection limits to 0.8 mg/L, with mean values that ranged from 0.22 to 0.53 
(Gedalia et al., 1959).  Interestingly, Gedalia et al. (1959) measured urinary fluoride in 
these pregnant women monthly between months 4 and 9 of pregnancy and found the 
mean value to decline (i.e., 0.53, 0.43, 0.34, 0.28, 0.22, and 0.29). In a study of 31 
pregnant women living in Poland, fluoride levels in spot urine samples from ranged from 
0.15 to 1.69 mg/l, with mean value in women sampled in the 28th and 33rd week of 
pregnancy being 0.65 and 0.84 mg/L respectively (Opydo-Szymaczek and Borysewicz-
Lewicka, 2005).  This study from Poland also documented that the urinary fluoride levels 
in the pregnant participants were lower than measured in a control group of non-pregnant, 
healthy women (1.3 mg/L), and showed there to be no difference in fluoride 
measurements between a fasting morning urine sample and a 24-hr collected urine 
sample.  For plasma, others have reported similar findings to ours.  For example, a study 
of 50 pregnant women sampled from Jerusalem found a mean plasma fluoride level of 
0.03 mg/L (Ron et al., 1986), and a study from Poland involving 35 women sampled 
during the third trimester of pregnancy measured 0.033-0.037 mg/L of plasma fluoride 
(Opydo-Szymaczek and Borysewicz-Lewicka 2006).  
 
Given concerns about the potential neurodevelopmental effects of fluoride 
exposure (Choi et al. 2012), there is a need to better understand exposures during 
pregnancy.  Further, an issue of increasing importance is determining whether there are 
time-related exposure windows of susceptibility to toxicant exposures especially during 
the prenatal period. Many lines of evidence now indicate such, including previous work 
by us concerning lead exposure in the ELEMENT cohort (Cantonwine et al. 2010; Hu et 
al. 2006). Here we were able to study fluoride levels in urine and plasma as pregnancy 
progressed. While no statistically significant changes were observed, creatinine-adjusted 
urinary fluoride levels increased until 22-23 weeks and then decreased until the end of 
pregnancy. These trends somewhat matched observations in older studies by Gedalia et 
al. (1959) and Hanhijarvi (1981) in which they also found non-significant reductions in 
the mean urinary fluoride in the final trimester.  Examination of the un-adjusted urinary 
fluoride levels revealed no significant changes, with the levels trending downward in a 
linear manner over the course of pregnancy.  The lack of significant changes in urinary or 
plasma fluoride during pregnancy was somewhat surprising given the number of 
physiological and metabolic changes occur during pregnancy, such as plasma volume 
expansion, mineral homeostasis and bone turnover, that could potentially affect fluoride 
pharmacokinetics and biomarker concentration levels. 
 
 An important feature of our study was the ability to relate the fluoride biomarkers 
with a range of sociodemographic measures.  In general there were no consistent 
associations though we note that statistically significant changes in urinary fluoride were 
found in relation to cohort (mothers from cohort #3-SF had ~17% lower mean levels than 
those sampled from cohort #2-PL) and education (mothers with less than 10 years of 
education had ~13% lower mean levels than those with more education) but these did not 
remain when the urinary fluoride values were adjusted for creatinine.  
 
 Despite a number of strengths (e.g., large sample size, multiple biomarkers, 
demographic factors, longitudinal design with repeated measures in the same 
individuals), there are potential limitations of our study that need mention.  Upon 
enrollment women were not screened for renal problems that could potentially affect the 
urinary fluoride levels.  The early morning 2nd voided urine samples and plasma samples 
we measured were not taken with the requirement that each subject be in the fasting state, 
which may have introduced variability.   However, the early morning 2nd void nature of 
the urine specimens would have reduced time-of-day variations driven by diurnal 
metabolic changes, and the adjustment by creatinine corrected for urinary dilution.  
Nonetheless, future studies should either provide 24-hour measures or measure samples 
that have been collected after fasting. This study was also not initially designed to address 
fluoride exposure, but we had archived urinary and plasma samples that served well to 
retrospectively investigate fluoride and in doing so, the fluoride levels we measured here 
were similar to previous reports. In addition, the study was not designed to ascertain 
specific sources of fluoride exposure.  The population from which our study was drawn 
(i.e., pregnant women residing in Mexico City) is mainly exposed to fluoride through 
ingestion of salt which is fluoridated to 250 ppm, though here we were not in a position 
to better characterize this exposure by collecting, for example, food items.  Regardless of 
such limitations, our work provides the largest characterization to date of urinary and 
plasma fluoride throughout pregnancy. These results can be used in future studies to 
explore exposure-related health outcomes in the ELEMENT cohort.  
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Table 1:  Fluoride concentrations (mg/L) in urine and plasma of pregnant women from the Early Life Exposures in Mexico to 
Environmental Toxicants (ELEMENT) cohort.  The “Average” represents data drawn from individuals who provided at least one 
sample. 
 
 
 
  Stage of Pregnancy N Mean SD Min 10% 25% 50% 75% 90% Max 
Creatinine-
adjusted 
urinary 
fluoride 
Early 436 0.92 0.46 0.15 0.47 0.63 0.82 1.14 1.40 4.43 
Mid 199 0.95 0.47 0.25 0.49 0.65 0.88 1.13 1.55 3.50 
Late  246 0.87 0.48 0.00 0.40 0.57 0.78 1.02 1.45 3.67 
Average 515 0.91 0.40 0.02 0.51 0.65 0.83 1.09 1.37 3.67 
Urinary 
fluoride 
Early 637 0.83 0.50 0.07 0.28 0.44 0.74 1.10 1.55 3.22 
Mid 514 0.83 0.55 0.02 0.28 0.42 0.72 1.08 1.55 3.44 
Late  369 0.78 0.52 0.01 0.23 0.40 0.69 1.05 1.44 2.87 
Average 825 0.83 0.45 0.01 0.33 0.51 0.76 1.06 1.41 3.22 
Plasma 
fluoride 
Early 220 0.0228 0.0222 0.0021 0.0045 0.0071 0.0145 0.0310 0.0558 0.1052 
Mid 255 0.0194 0.0166 0.0022 0.0052 0.0077 0.0140 0.0240 0.0422 0.0777 
Late  152 0.0184 0.0171 0.0028 0.0047 0.0067 0.0121 0.0242 0.0462 0.0819 
Average 330 0.0221 0.0164 0.0035 0.0066 0.0091 0.0172 0.0299 0.0456 0.0786 
 
 
 
Table 2: Spearman correlation coefficients relating fluoride levels in urine (creatinine-adjusted) and plasma at three different stages of 
pregnancy among participating mothers in the Early Life Exposures in Mexico to Environmental Toxicants (ELEMENT) cohort.  In 
each cell, the first line is the correlation coefficient, followed by the p-value (line 2) and the sample size (line 3).  
 
  Stage of Pregnancy 
Urine    Plasma  
Early Mid  Late   Early  Mid  Late  
 
 
Early 
1.00 0.39 0.21 
  
0.29 0.03 0.09 
 
 - <0.001 <0.001 0.004 0.72 0.42 
 
 436 145 202 97 136 90 
 
 
Mid   
1.00 0.29 
  Only N=1 subject had both plasma and urine  from mid pregnancy Urine - 0.01 
 
 199 90 
 
 
Late     
1.00 
  
0.11 -0.1 -0.24 
 
 - 0.40 0.39 0.07 
 
 246 59 76 56 
 
 
Early         
1.00 0.44 0.14 
 
 - <0.001 0.21 
 
 220 162 82 
 
 
Mid           
1.00 0.38 
Plasma - <0.001 
 
 255 133 
 
 
Late         
1.00 
 
 - 
 
 152 
 
  
 
 
Table 3:  Fluoride levels in urine (creatinine-adjusted) and plasma (values averaged across three different stages of pregnancy) among 
participating mothers in the Early Life Exposures in Mexico to Environmental Toxicants (ELEMENT) cohort according to key 
sociodemographic variables.  Further details on the cohorts can be found in Hu et al. (2006) and Afeiche et al. (2011). 
 
  Urinary Fluoride, mg/L Urinary Fluoride (creatinine‐adjusted), 
mg/L 
Plasma Fluoride, mg/L
  N(%)  Mean (SE) p‐value N(%) Mean (SE) p‐value N(%)  Mean (SE) p‐value
Married 
 
No  241(29.2)  0.79(0.03)  0.50  155(30.1)  0.88(0.03)  0.84  96(29.1)  0.024(0.002)  0.07 Yes  584(70.8)  0.82(0.02)  360(69.9)  0.88(0.02)  234(70.9)  0.020(0.001) 
Maternal 
Age 
18‐23 years  261(31.6)  0.80(0.03) 
0.47 
169(32.8)  0.86(0.03) 
0.31 
98(29.7)  0.021(0.002) 
0.67 24‐28 years  285(34.5)  0.79(0.03)  172(33.4)  0.87(0.03)  116(35.2)  0.020(0.002) 
29‐44 years  279(33.8)  0.84(0.03)  174(33.8)  0.91(0.03)  116(35.2)  0.022(0.002) 
Cohort 
PL   232(28.1)  0.93(0.03)  <.0001  150(29.1)  0.90(0.03)  0.42  53(16.1)  0.024(0.004)  0.35 SF   593(71.9)  0.77(0.02)  365(70.9)  0.87(0.02)  277(83.9)  0.021(0.001) 
Educatio
n 
0‐9 years   371(45.0)  0.75(0.02) 
0.0007 
227(44.1)  0.86(0.02) 
0.29 
139(42.1)  0.021(0.001) 
0.15 10‐12 years   336(40.7)  0.87(0.02)  217(42.1)  0.91(0.02)  138(41.8)  0.022(0.001) 
>12 years   118(14.3)  0.85(0.04)  71(13.8)  0.86(0.04)  53(16.1)  0.017(0.002) 
Child Sex 
Male  342(49.6)  0.83(0.02)  0.32  239(48.0)  0.90(0.02)  0.18  123(49.2)  0.022(0.001)  0.15 Female  347(50.4)  0.79(0.02)  259(52.0)  0.86(0.02)  127(50.8)  0.020(0.001) 
Firstborn 
No  551(66.8)  0.82(0.02)  0.22  340(66.0)  0.88(0.02)  0.83  232(70.3)  0.022(0.001)  0.25 Yes  274(33.2)  0.78(0.03)  175(34.0)  0.88(0.03)  98(29.7)  0.019(0.002) 
Smoking 
Status 
Never  407(49.9)  0.83(0.02) 
0.10 
257(50.3)  0.87(0.02) 
0.73 
163(50.5)  0.021(0.001) 
0.84 
History of 
smoking  390(47.9)  0.78(0.02)  243(47.6)  0.89(0.02)  149(46.1)  0.021(0.001) 
Smoked 
during 
pregnancy 
18(2.2)  0.95(0.10)  11(2.2)  0.91(0.10)  11(3.4)  0.018(0.005) 
 
Figure Legends 
 
 
Figure 1: Flow chart of study population drawn from the Early Life Exposures in Mexico 
to Environmental Toxicants (ELEMENT) cohort.  
 
Figure 2: Box and whisker plots of creatinine-adjusted urinary (plot 2A) and plasma (plot 
2B) fluoride levels in pregnant women from the Early Life Exposures in Mexico to 
Environmental Toxicants (ELEMENT) cohort. Values are shown across three stages of 
pregnancy corresponding to approximately 13.5, 25.3, and 34 weeks of pregnancy.   
 
Figure 3: Creatinine-adjusted urinary (plots 3A and 3B) and plasma (plots 3C and 3D) 
fluoride levels in pregnant women from the Early Life Exposures in Mexico to 
Environmental Toxicants (ELEMENT) cohort according to sampling time expressed as 
gestational weeks. Measured values are shown (plots 3A and 3C) as are the trend lines 
(plots 3B and 3D).   
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Supplemental Table 1:  A matched comparison of creatinine-adjusted and unadjusted urinary fluoride concentrations (mg/L) in 
samples of pregnant women from the Early Life Exposures in Mexico to Environmental Toxicants (ELEMENT) cohort. The 
“Average” represents data drawn from individuals who provided at least one sample. 
 
 
 
 
  Stage of Pregnancy N Mean SD Min 10% 25% 50% 75% 90% Max 
Creatinine-
adjusted 
urinary 
fluoride 
Early 436 0.92 0.46 0.15 0.47 0.63 0.82 1.14 1.40 4.43 
Mid 199 0.95 0.47 0.25 0.49 0.65 0.88 1.13 1.55 3.50 
Late 246 0.87 0.48 0.00 0.40 0.57 0.78 1.02 1.45 3.67 
Average 515 0.91 0.40 0.02 0.51 0.65 0.83 1.09 1.37 3.67 
Unadjusted 
urinary 
fluoride 
Early 436 0.83 0.50 0.07 0.28 0.44 0.74 1.10 1.59 2.53 
Mid 199 0.90 0.57 0.10 0.31 0.47 0.81 1.15 1.61 3.25 
Late 246 0.80 0.53 0.01 0.26 0.40 0.68 1.05 1.48 2.70 
Average 515 0.85 0.46 0.01 0.34 0.50 0.78 1.08 1.46 2.53 
 
 
